If we were to look at the results from a clinical response percentage point of view that being full / partial /stable / none, then as ann stated 7 of the 8 patients had an efficacy response of varying degrees. The response rate of improving these very sick people that are otherwise chemo resistant with little to no other known medicine to help them was 87.5% improvement. To me this is an outstanding result which seems to be somewhat lost in translation to the market. Unless I’m missing something here and have maxter’s rose coloured glasses on.
The standout point is 1 of the 2 patients with ER+ disease treated thus far had a full pathologic response, meaning disappearance of disease upon microscopic assessment. Wow this is a sensational! I know early days and only 2 patients with ER+ were in the 1b trial, but if we prove our pathologic response is better than current treatments as stated currently being 15%, then this potentially a game changer IMO. Again well done PTX, looking forward to further AML & ovarian results.
PTX Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
